Drugs / PD1-BCMA-CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05308875 | Mar 2024 → Jan 2025 | plasma cell myeloma | Bioray Laboratories | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD1-BCMA-CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05308875 ↗ |
| Action | Deplete | “could identify and kill myeloma cells in the subjects” NCT05308875 ↗ |
| Modality | Cell therapy | “subject self-derived T cells” NCT05308875 ↗ |
| Route | Intravenous | “administered intravenously (i.v.)” NCT05308875 ↗ |